Results to be Presented at the European Society for Cardiology Congress Demonstrate Differential Effects During Endothelial Dysfunction in Cell Studies A manuscript entitled “Metabolic, Intestinal, ...
Sotagliflozin (Inpefa) had a 23% risk reduction for major adverse cardiovascular events in high-risk patients with type 2 diabetes and chronic kidney disease. The dual SGLT1/2 inhibitor yielded a 32% ...
An FDA panel on Thursday recommended against sotagliflozin as an adjunct to insulin for patients with type 1 diabetes (T1D) and mild-to-moderate chronic kidney disease (CKD). With a vote of 11-3, the ...
THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) today announced the outcome of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic ...
The dual sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor sotagliflozin reduced major adverse cardiovascular events, with significant reductions in the individual outcomes of myocardial ...
Helps individuals living with heart failure, or those at risk of developing it, by reducing complications and lowering the risk of serious cardiovascular problems ...
Time to clinical benefit was assessed. The x-axis represents time from randomization, and the y-axis represents the degree of benefit at that time, as measured by the hazard ratio shown in blue. The ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Sotagliflozin was linked to lower HbA1c for users with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback